A soothing, firming and anti-wrinkle composition, application and cosmetics

Abstract

The present invention belongs to the field of daily chemicals, and discloses a soothing, firming and anti-wrinkle composition, comprising an extract of cherimoya fruit and an extract of Withania somnifera root; the weight ratio of the extract of cherimoya fruit and the extract of Withania somnifera root is 0.005-5:0.01-3.5. After testing, it is found that the composition has obvious synergy in histamine stimulation and inhibition of inflammatory factors, and the composition has excellent firming and anti-wrinkle effects. At the same time, the present invention also discloses the application of the above composition.

Description

Technical Field

[0001] The invention belongs to the field of new daily chemical materials, and particularly relates to a soothing, firming and anti-wrinkle composition, application and cosmetics. Background Art

[0002] The main function of the cherimoya fruit extract has been disclosed to be soothing, which can be specifically seen in the following documents: Publication No. CN118717553A, the subject is a multi-effect soothing composition containing ectoine and its application; Publication No. CN116035979A, the subject is a soothing repairing composition, essence and its preparation method;

[0003] One of the main active ingredients of Withania somnifera (root) extract is withanolide. The main public effects of Withania somnifera (root) extract are firming and anti-wrinkle, antioxidant and whitening effects. The most core effect is firming and anti-wrinkle.

[0004] The combination of cherimoya fruit extract and Withania somnifera (root) extract, in theory, has the dual effects of firming, anti-wrinkle and soothing.

[0005] In the further study of the above two substances in this project, some other more peculiar phenomena were discovered, and thus this application was filed. Summary of the invention

[0006] Based on this, the first object of the present invention is to provide a soothing, firming and anti-wrinkle composition. After testing, it was found that the composition has obvious synergy in histamine stimulation and inhibition of inflammatory factors. At the same time, the composition has excellent firming and anti-wrinkle effects.

[0007] Meanwhile, the invention also discloses the application of the composition.

[0008] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:

[0009] A soothing, firming and anti-wrinkle composition comprising Annona mume fruit extract and Withania somnifera root extract;

[0010] The weight ratio of the Annona cherimoya fruit extract to the Withania somnifera root extract is 0.005-5:0.01-3.5.

[0011] Published literature records that the core function of cherimoya fruit extract is soothing; the core function of Withania somnifera root extract is firming and anti-wrinkle, and it also has antioxidant and whitening effects.

[0012] The cherimoya fruit extract and Withania somnifera root extract of the present invention are both commercial raw materials. In practical applications, whether it is a scheme using commercial raw materials as the ratio or a scheme using effective ingredients as the ratio, as long as they fall within the relevant content range of this case, they should be deemed to be within the protection scope of this application.

[0013] The present invention achieves the purpose of synergistic synergy in soothing and reducing redness by comprehensively utilizing the above two raw materials; the specific principle is:

[0014] At the beginning of the development of this invention, we found through a large number of literature studies that CCN1 is a potential key protein linking sensitivity and aging. When exposed to ultraviolet rays, the expression level of CCN1 increases, which will cause collagen degradation and lead to skin aging, trigger inflammatory reactions, damage the barrier, and increase the sensitivity of key receptors (TRPV1, TPRA1, ETAR, H1R, NK1R) that cause skin redness, itching and pain, and aggravate skin sensitivity. At the same time, after receiving external stimuli, TRPV1, TPRA1, ETAR, H1R, and NK1R on the skin will also be directly activated, inducing subsequent inflammatory reactions, thereby causing sensitive problems such as redness, stinging, itching, and inflammatory aging problems. Therefore, sensitivity and aging problems promote each other, and inhibiting CCN1 and redness, itching and pain-related receptors is an effective potential way to tighten and anti-wrinkle sensitive skin. In the early stage, we verified that Withania somnifera has a significant effect in inhibiting the expression of CCN1, and also screened out the active ingredient with the greatest affinity for the red, itch and pain receptor protein through the AI ​​molecular docking model. This active ingredient is a characteristic component of the Annona sudorifera fruit extract. Both in vivo and in vitro results verified that the Annona sudorifera fruit extract has obvious soothing and redness-reducing effects. Therefore, the present invention selects the above two for compounding to achieve the effect of firming and anti-wrinkle of sensitive skin.

[0015] In the above soothing, firming and anti-wrinkle composition, the weight ratio of the Annona mume fruit extract to the Withania somnifera root extract is 0.05-5:0.05-3.5.

[0016] At the same time, the present invention also discloses the use of the soothing, firming and anti-wrinkle composition as described above in preparing cosmetics.

[0017] In addition, the present invention also discloses a cosmetic containing the soothing, firming and anti-wrinkle composition.

[0018] The above-mentioned cosmetic contains 0.015-8.5 wt % of the soothing, firming and anti-wrinkle composition.

[0019] The above-mentioned cosmetic contains 0.1 to 8.5 wt % of the soothing, firming and anti-wrinkle composition.

[0020] The beneficial effects of the present invention are:

[0021] The present invention adopts the compound of Annona chebula fruit extract and Withania somnifera root extract to achieve the purpose of synergistic enhancement in soothing and reducing redness;

[0022] The histamine calcium flow experiment and the in vitro inflammatory factor inhibition experiment proved that the two have synergistic effects in soothing and inhibiting inflammatory factors;

[0023] Through human efficacy experiments, the soothing efficacy trend of using Annona cherimoya fruit extract and Withania somnifera root extract alone and the soothing effect of the two in different proportions were further revealed. The experimental results further confirmed that the two have soothing synergy.

[0024] Through human body firming and anti-wrinkle experiments, it is demonstrated that the two have better firming and anti-wrinkle effects when combined in different proportions.

[0025] The above results verified the soothing mechanism of the combination of the present invention from both in vitro and human aspects. At the same time, through the redness soothing experiment and firming and anti-wrinkle experiment in the human body, it was further demonstrated that inhibiting CCN1 and redness, itch and pain related receptors is an effective potential way to firm and anti-wrinkle sensitive skin.

[0026] Through repeated experimental studies and verifications, the combination of the present invention with soothing, firming and anti-wrinkle effects was obtained. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 A graph showing the effects of different substances on improving redness in the capsaicin-induced redness model. DETAILED DESCRIPTION

[0028] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0029] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0030] The trade name of the AnnonaSense CLR™ AP of the AnnonaSense CLR™ AP was purchased from CLR ChemischesLaboratorium; the active ingredient is: Annona CHERIMOLIA fruit extract; the content of the active ingredient is about 1wt% (batch number: 3243352);

[0031] The trade name of Withania somnifera root extract is Withania somnifera Energy, which is purchased from Guangdong Heji Biotechnology Co., Ltd.; the active ingredient is: Withania somnifera root extract; the content of the active ingredient is 4.8 ~ 6.5wt% (the content used this time is about 5.56%, batch number: 240917-0586); extraction process: the dried Withania somnifera root is crushed and then extracted with water under controlled temperature and time, the residue is removed by centrifugation and filter pressing, and the product is concentrated by low-temperature nanofiltration membrane, and the raw material is obtained by fine filtration after compounding with preservatives.

[0032] The trade name of palmitoyl tripeptide-5 solution is JYMed®COL 1000, which is purchased from Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. The active ingredient is: palmitoyl tripeptide-5; the content of the active ingredient is ≥0.1wt% (the content used this time is about 0.1%, batch number: WKC0241001);

[0033] The trade name of ginseng root extract is ginseng extract (Gerbex Ginseng), which is provided by Shanghai Jiakai Biotechnology Co., Ltd. The active ingredient is: ginseng root extract, and the active ingredient content is about 0.5wt% (batch number: HS01142DJ28078).

[0034] Part I Basic Functional Verification of the Composition

[0035] This part is divided into 2 experiments, which evaluate the relevant functions of the combination of the present invention from the perspective of histamine stimulation and inhibition of inflammatory factors; the details are as follows.

[0036] 1. Histamine Calcium Flux Experiment

[0037] Materials and methods

[0038] 1.1 Main reagents and consumables: NHEK (normal human primary keratinocytes) cells, EMEM culture medium, PBS Tablets, 0.25% Trypsin-EDTA (1X), double antibody (Pen Strep, PS), 96-well black-walled transparent bottom plate, Fluo-4 calcium ion detection kit, histamine, loratadine, etc.

[0039] 1.2 Instruments and equipment: constant temperature water bath, cell imaging multifunctional microplate detector, fully automatic cell analyzer, carbon dioxide incubator, biological safety cabinet, etc.

[0040] 2. Principle of the method

[0041] The itch-related HR1 receptor can be activated by the specific itch-inducing agent histamine, thereby promoting the release of downstream signaling molecules such as phospholipase A2 (PLA2), lipoxygenase (LOX), and protein kinase C (PKC), further activating itch-related ion channels such as transient receptor potential vanilloid subtype 1 (TRPV1), transient receptor potential ankyrin 1 (TRPA1), and other calcium ion channels, promoting the opening of Ca 2+ channels. 2+ Influx of calcium in the cells completes the conduction of itch signals. NHEK cells are normal human epidermal keratinocytes that express a large number of HR1 receptors and calcium ion channels. Therefore, NHEK cells can be used to detect the relative level of intracellular calcium before and after histamine stimulation with the help of the Fluo-4 calcium ion detection kit to evaluate the efficacy of the raw materials to relieve itch.

[0042] 3. Experimental Procedure

[0043] 3.1 Prepare NHEK cells: Prepare a cell suspension with a density of 2.0×10^4 / mL, take 100 μL into a 96-well black-walled transparent bottom plate, and culture in a 37℃ 5% CO2 incubator for 24 h.

[0044] 3.2 Sample preincubation: Preincubate for about 4 hours.

[0045] Positive group: 1 μM loratadine;

[0046] The sample group preparation and administration are shown in Table 1 below:

[0047] Table 1 Experimental conditions

[0048] Group Sample pre-incubation Stimulants Blank Group Culture medium / Model Group Culture medium 10 μM histamine Positive group Culture medium + loratadine 10 μM histamine Sample set 1 Culture medium + 0.9wt% AnnonaSense CLR™ AP 10 μM histamine Sample set 2 Culture medium + 0.1wt% Withania somnifera energy 10 μM histamine Sample set 3 Culture medium + 0.9wt% AnnonaSense CLR™ AP + 0.1wt% Withania somnifera 10 μM histamine

[0049] 3.3 Incubate the dye: Incubate the dye according to the Fluo-4 Calcium Assay Kit procedure.

[0050] 3.4 Secondary incubation of samples: Secondary incubation of samples was performed for approximately 30 min.

[0051] 3.5 Detection: After adding histamine stimulation, the fluorescence intensity data was detected using the kinetic mode of the cell imaging multi-function microplate reader.

[0052] 3.6 Data processing: The maximum fluorescence intensity data after the addition of histamine stimulation was selected and divided by the fluorescence intensity data before stimulation to obtain the relative fluorescence intensity.

[0053] 3.7 Data analysis: Each group had ≥3 valid data points, and the average value of the relative fluorescence intensity of each group was calculated. Compared with the relative fluorescence intensity value of the model group, the smaller the relative fluorescence intensity value of the sample group was, the better the efficacy of the sample in relieving histamine-induced itching was.

[0054] Inhibition rate (%) = (relative fluorescence intensity of the model group - relative fluorescence intensity of the sample group) / relative fluorescence intensity of the model group × 100%.

[0055] 4. Experimental Results

[0056] The experimental results are shown in Table 2;

[0057] Table 2 Histamine calcium flux test results

[0058] sample Fluorescence intensity P-value Inhibition rate / % Blank Group 0.451±0.013 / Model Group 1±0.055 / Positive group 0.569±0.015*** ＜0.001 43.10 Sample set 1 0.958±0.039 0.157 / Sample set 2 0.975±0.104 0.618 / Sample set 3 0.807±0.098** 0.002 19.30

[0059] Conclusion: In the histamine calcium flux detection method, 0.9% AnnonaSense CLR™ AP and 0.1% Withania somnifera Energy, when used alone, had no effect on relieving histamine-induced itching; 0.9% AnnonaSense CLR™ AP and 0.1% Withania somnifera Energy, when combined, had the effect of relieving histamine-induced itching, indicating that the Annona guajava fruit extract and the Withania somnifera root extract had synergistic effects at this experimental concentration.

[0060] 2. In vitro inflammatory factor inhibition experiment

[0061] 1. Materials and Methods

[0062] 1.1 Main reagents and consumables: RPMI 1640 (GIBCO, C11875500BT), fetal bovine serum (FBS) (GIBCO, catalog number: 10099141), THP-1 (human acute monocytic macrophage leukemia cells) (China Center for Type Culture Collection, catalog number: GDC0100), RaPure Total RNA Kit (Magen, catalog number: R4011), HiScript II Q RT SuperMixfor qPCR (+gDNA wiper) (Novozyme, catalog number: R223-01), PowerUpTM SYBRTM Green Master Mix (Thermo Fisher, A25742), LPS Derived from Escherichia coli 0111:B4 (sigma, L4391, EC: 297-473-0), dexamethasone (sigma, D4902, CAS: 50-02-2), β-mercaptoethanol (sigma, M3148, CAS: 60-24-2);

[0063] 1.2 Instruments and equipment: Real-time fluorescence quantitative PCR system (Applied Biosystems™, model: QuantStudio™ 1); gene thermal cycler (Hangzhou Boheng Technology Co., Ltd., model: GE4852T), micro-volume spectrophotometer (Hangzhou Aosheng Instrument Co., Ltd., model: Nano-500); cell counter (Beckman Coulter, model: Vicell XRII).

[0064] 2. Principle of the method

[0065] Lipopolysaccharide (LPS) is a component of the outer membrane of all Gram-negative bacteria. The administration of LPS is often used to study inflammatory-related behaviors and changes. Human acute monocytic macrophage leukemia cells (THP-1) are a strain of human immune cells that are often used to establish in vitro inflammatory cell models. Therefore, LPS was used to stimulate THP-1 to establish an inflammatory cell model, and qPCR was used to detect the expression of inflammatory factors such as TNF-a, IL-6 and IL-1β in THP-1 to characterize the inflammatory response of THP-1; thereby evaluating whether the sample has the activity of inhibiting inflammatory factors.

[0066] 3. Experimental Procedure

[0067] 3.1 Preparation of THP-1 cells: THP-1 human acute monocytic macrophage leukemia cells were seeded in a 24-well plate at 5 x 10^5 cells / well / 1 mL, and samples of different concentrations were added and cultured in a 37°C 5% CO2 incubator for 24 h.

[0068] 3.2 Sample pre-incubation: Add lipopolysaccharide (LPS) and incubate for about 4 hours.

[0069] Positive group: dexamethasone (final concentration 10 μg / ml);

[0070] Model group: lipopolysaccharide LPS (final concentration 1 μg / ml);

[0071] Sample group 4: AnnonaSense CLR™ AP (final concentration 0.1%);

[0072] Sample group 5: Withania somnifera (final concentration 0.05%);

[0073] Sample group 6: AnnonaSense CLR™ AP (final concentration 0.1%) + Withania somnifera (final concentration 0.05%).

[0074] 4. Experimental Results

[0075] The experimental results are shown in Table 3;

[0076] Table 3 Inhibition of inflammatory factors expression

[0077]

[0078] Note: “*” indicates significant difference compared with the NC group, where “*” indicates P<0.05; “**” indicates P<0.01; “***” indicates P<0.001.

[0079] Conclusion: In this inflammatory model, 0.1% AnnonaSense CLR™ AP and 0.05% Withania somnifera Energy alone had no effect on the expression of inflammatory factors IL-1β, IL-8 and TNF-α mRNA. When 0.1% AnnonaSense CLR™ AP and 0.05% Withania somnifera Energy were used in combination, they could significantly inhibit the expression of inflammatory factors IL-1β, IL-8 and TNF-α mRNA, indicating that in this model, Annona guajava fruit extract and Withania somnifera root extract have synergistic effects at this experimental concentration.

[0080] Part II Human efficacy verification of the composition

[0081] The composition of the present invention is applied to a cream. The cream formula can refer to Table 4, and the composition formula can refer to Table 5;

[0082] The preparation method of the cream is:

[0083] 1. Heat the raw material of phase A to 80~90℃ until it is completely dissolved;

[0084] 2. Add the ingredients of phase B into the main pot and heat to 80-90°C until completely dissolved;

[0085] 3. Add phase A into the main pot of phase B and emulsify and homogenize at 80-90°C for 3-6 minutes;

[0086] 4. Cool down to below 60℃ and add dissolved phase C into the main pot;

[0087] 6. Add dissolved phase E into the main pot and stir;

[0088] 7. Cool down to below 45℃ and filter out the material.

[0089] Table 4 Cream formula

[0090]

[0091] Table 5 Composition formula (content based on commercial raw materials)

[0092] Product Name AnnonaSense CLR™ AP / wt% Withania somnifera energy / wt% Ginseng extract / wt% JYMed®COL 1000 / wt% Total amount / wt% Active ingredients Annona Fruit Extract Withania somnifera root extract Ginseng Root Extract Palmitoyl Tripeptide-5 / blank / / / / 0 Example 1 0.9 0.1 / / 1 Example 2 0.05 0.05 / / 0.1 Example 3 0.05 3.5 / / 3.55 Example 4 5 0.05 / / 5.05 Example 5 5 3.5 8.5 Comparative Example 1 1 0 / / 1 Comparative Example 2 0 1 / / 1 Comparative Example 3 0.1 / / / 0.1 Comparative Example 4 / 0.1 / / 0.1 Comparative Example 5 8.5 / / / 8.5 Comparative Example 6 / 8.5 / / 8.5 Comparative Example 7 0.9 / 0.1 / 1 Comparative Example 8 0.9 / / 0.1 1 Comparative Example 9 / / 0.1 / 0.1 Comparative Example 10 / / / 0.1 0.1

[0093] 1. Capsaicin soothing experiment (for tingling and redness of sensitive skin)

[0094] 1.1 Experimental basis

[0095] TRPV1, also known as capsaicin receptor, is currently considered to be the key target of sensitive muscle nerve hyperreactivity and plays a key role in nociceptive responses. High temperature, overly acidic environment, excessive phenoxyethanol and ethanol, and capsaicin can all activate it. When the TRPV1 receptor expressed on neurons is activated, it induces a large influx of calcium ions and generates action potentials. The electrical signals are transmitted along the nerves through the thalamus and then generate heat and pain in the cerebral cortex, which in turn triggers an inflammatory response in the skin, interfering with barrier repair, causing local skin redness, increased sensitivity, and accelerated skin aging.

[0096] 1.2 Experimental methods

[0097] Subjects and number: 15 Asian adults aged 18-55, male and female;

[0098] Test site: inner side of the front end of the arm;

[0099] Environmental conditions: Temperature: (21±1)℃, Humidity: (50±10)%;

[0100] Reagents, instruments and materials: skin sensitivity tester (TIVI700, WheelsBridge, Sweden), spectrophotometer (CM700D, Konica Minolta, Japan), adjustable pipette (M100E, Gilson, France), 0.1% capsaicin solution (dissolved in 75% alcohol), 18mm spot tester, dry facial tissue, 75% alcohol, lens cleaning paper, filter paper, positioning card;

[0101] Specific operation: Add 200μL of 0.1% capsaicin ethanol solution to the patch tester, stick it on the designated inner forearm area, and apply a closed patch for 15 minutes. Remove the patch tester and balance it for 10 minutes. Select subjects with a redness rate ≥40% to continue testing. Subjects with a redness rate <40% are not included in this experiment. Use 25μL of sample once on the test area, and evaluate the soothing (redness) and soothing (stinging) effects of the sample by measuring the TIVI value before using capsaicin solution (Toriginal), before using capsaicin solution but not using the sample (T0), and 15min and 30min after using the sample (T15min, T30min), the a* value of the skin surface, the redness score assessed by the technician, and the stinging score self-assessed by the subject (0-10 points).

[0102] N min red fading rate (%) = (a* 0min - a* nmin )×100% / (a* 0min - a* Toriginal );

[0103] Note:

[0104] ① Redness score evaluation criteria:

[0105] 0 points: no redness on the skin surface;

[0106] 1 point: very slight, noticeable reddish color;

[0107] 2-4 points: slight redness on the skin surface (obvious light red);

[0108] 5-7 points: moderate redness on the skin surface, the redness is clearly discernible (dark red);

[0109] 8-10 points: severe redness on the skin surface (dark or bright red);

[0110] ② Pain score evaluation criteria:

[0111] 0 points: no stinging pain was felt;

[0112] 1-3 points: slight tingling, which can be felt;

[0113] 4-6 points: moderate stabbing pain, which can be clearly felt;

[0114] 7-9 points: severe stabbing pain, felt strongly;

[0115] 10 points: Severe stinging pain, unbearable.

[0116] 1.3 Experimental results refer to Table 6;

[0117] Table 6 Capsaicin stimulation, soothing and redness fading test results

[0118]

[0119] Result analysis:

[0120] 1. Comparative Examples 1, 3 and 5 show that as the concentration of AnnonaSenseCLR™ AP increases, its redness fading rate will increase, but a higher concentration is required to show the actual redness fading rate effect;

[0121] It can be seen from Comparative Examples 2, 4 and 6 that as the concentration of Withania somnifera root extract increases, its redness fading rate first increases and then decreases, that is, when the dosage of Withania somnifera root extract reaches a higher concentration, the redness fading effect will be inhibited.

[0122] The above results indicate that the dosage of Withania somnifera root extract should be taken at a more appropriate value, and the dosage of Annona chebula fruit extract can be increased appropriately.

[0123] 2. It can be seen from Example 1, Comparative Example 1 and Comparative Example 2 that when the total dosage of the two is 1wt% based on the commercial raw materials and the ratio is 9:1, they show synergistic effects in soothing and fading redness;

[0124] It can be seen from Example 2, Comparative Example 3 and Comparative Example 4 that when the total dosage of the two is 0.1wt% based on the commercial raw materials and the ratio is 1:1, they show synergistic effects in soothing and fading redness;

[0125] It can be seen from Example 5, Comparative Example 5 and Comparative Example 6 that when the total amount of the two is 8.5 wt% based on the commercial raw materials and the ratio is 5:3.5, they show synergistic effects in soothing and fading redness;

[0126] 3. It can be seen from Example 1 and Comparative Examples 7 to 10 that when ginseng root extract and palmitoyl tripeptide-5 are used, they do not show obvious synergy with the cherimoya fruit extract.

[0127] at the same time, Figure 1 The images show the effects of different substances in improving redness in the capsaicin-induced redness model. The images are collected and analyzed by Tivi 700. The closer the image color is to red, the more severe the skin redness is.

[0128] pass Figure 1 It can be seen that the blank group, comparative example 1 and comparative example 2 did not show obvious improvement effects, while example 1 had obvious improvement effects.

[0129] 2. Human Experimental Soothing Experiment: Histamine Modeling-Redness and Itch Experiment Basis

[0130] Histamine stimulation is a classic model for inducing skin redness and itching. When histamine binds to histamine receptors on the skin, it quickly triggers a series of signal transduction processes, leading to capillary dilation, increased vascular permeability, and the release of inflammatory mediators, which cause skin redness; and histamine and subsequent itching mediators stimulate nerve endings to produce itching. Therefore, this experiment uses the histamine model to test the ability to remove redness and relieve itching.

[0131] Experimental methods:

[0132] Subjects and number: 15 Asian adults aged 18-55, male and female;

[0133] Test site: inner side of the front end of the arm;

[0134] Environmental conditions: Temperature: (21±1)℃, Humidity: (50±10)%;

[0135] Reagent materials and instruments: histamine phosphate, medical pricking needles, soothing samples;

[0136] Test method (puncture method): Use a puncture needle to puncture the test area on the inside of the arm, with no bleeding as the standard; use 1% histamine phosphate solution, drip 0.02ml on the inside of the arm, absorb the histamine solution after 5 minutes, and wait for about 10 minutes. Apply 0.02g of sample to the 2*2cm area of ​​the sample area and the control area, record the redness and itching of the arm at each time point, and score and record. The technician evaluates the test site at the corresponding time point (0min, 5min, 15min) at the test time point.

[0137] Histamine pain improvement rate (%) = (pain score at 0 min after histamine pricking modeling - pain score at n minutes after histamine pricking modeling) × 100% / pain score at 0 min after histamine pricking modeling;

[0138] Histamine redness improvement rate (%) = (redness score at 0 min after histamine pricking modeling - redness score at n minutes after histamine pricking modeling) × 100% / redness score at 0 min after histamine pricking modeling;

[0139] Note: ① Itch / pain scoring criteria:

[0140] 5 points: obvious severe itching / pain, can't help scratching / unbearable;

[0141] 4 points: obvious itching / pain, want to scratch from time to time / can tolerate it;

[0142] 3 points: slight itching / pain, no treatment is required;

[0143] 2 points: vague itching / pain, which cannot be accurately described;

[0144] 1 point: No itching / pain.

[0145] ② Redness rating criteria:

[0146] 5 points: obvious and severe redness;

[0147] 4 points: obvious redness;

[0148] 3 points: moderate redness;

[0149] 2 points: very slight redness;

[0150] 1 point: No redness, same skin color as untreated area.

[0151] The experimental results are shown in Table 7;

[0152] Table 7 Histamine phosphate stimulation, soothing and redness fading test results

[0153]

[0154] Result analysis:

[0155] 1. Referring to Comparative Examples 1 to 4, the difference from the above-mentioned soothing redness-fading test results is that in the soothing redness-fading test of capsaicin modeling, the Annona fruit extract and the Withania somnifera root extract showed almost no effect at low concentrations; in this histamine modeling experiment, the Annona fruit extract and the Withania somnifera root extract showed excellent soothing redness-fading effects at low concentrations, among which, it can be seen from Comparative Examples 3, 1, and 5 that the soothing redness-fading effect of the Annona fruit extract is positively correlated with the concentration; it can be seen from Comparative Examples 4, 2, and 6 that the soothing redness-fading effect of the Withania somnifera root extract is positively correlated with the concentration;

[0156] 2. It can be seen from Example 1, Comparative Example 1 and Comparative Example 2 that when the total dosage of the two is 1wt% based on the commercial raw materials and the ratio is 9:1, they show synergistic effects in soothing and fading redness;

[0157] It can be seen from Example 2, Comparative Example 3 and Comparative Example 4 that when the total dosage of the two is 0.1wt% based on the commercial raw materials and the ratio is 1:1, they show synergistic effects in soothing and fading redness;

[0158] It can be seen from Example 5, Comparative Example 5 and Comparative Example 6 that when the total dosage of the two is 8.5 wt% based on the commercial raw materials and the ratio is 5:3.5, they show synergistic effects in soothing and fading redness;

[0159] 3. It can be seen from Example 1 and Comparative Examples 7 to 10 that when ginseng root extract is used, it does not show obvious synergy with the Annona fruit extract. When palmitoyl tripeptide-5 is used, it shows a certain synergy in soothing and fading redness, but the overall synergy level is not as good as that of the Withania somnifera root extract.

[0160] 3. Human body firming and anti-wrinkle data:

[0161] 3.1 Experimental Purpose

[0162] Two groups of Asian adult subjects (20*2 persons) were selected and used the samples on their faces for 28 consecutive days. The repair, firming, elasticity and anti-wrinkle effects of the samples were evaluated by measuring the changes in the transepidermal water loss rate (TEWL), skin elasticity (Q1 value), skin firmness (F4 value) and cheek wrinkle-related parameters (number of wrinkles, wrinkle area, average wrinkle depth, wrinkle roughness (Rz value)) before using the samples (D0) and on the 7th, 14th and 28th days (D7, D14, D28) after using the samples.

[0163] 3.2 Basic principles

[0164] The client needs to provide a signed and sealed sample safety declaration before the experiment to ensure the safety of the test samples. The safety declaration is used to ensure that the test samples will not cause foreseeable risks of harm to the health of the subjects when used under the conditions specified in the protocol;

[0165] Human clinical trials should comply with the basic principles of the International Declaration of Helsinki.

[0166] 3.3 Subject requirements:

[0167] 40 healthy Asian adult women aged 35 to 60 years old, who were self-consciously sensitive and had sensitive skin according to the sensitive skin screening questionnaire, had a basic value of transepidermal water loss rate of facial skin of 12-30 g / h·m 2 ; The basic value of facial skin elasticity (Q1 value) is 0.35~0.55; Those who feel that their facial skin is loose and the basic value of facial skin firmness (F4 value) is greater than 5; and have facial wrinkles. During the test, the samples and other precautions must be strictly followed.

[0168] 3.4 Test instruments and materials:

[0169] (1) Main instruments: skin fast optical imaging system (VISIO 4D, EOTECH, France), skin water loss test probe (Tewameter TM300, CK, Germany), skin elasticity tester (Cutometer MPA580, CK, Germany), electronic balance (JJ1000, Shuangjie Testing Instrument Factory, Changshu, China);

[0170] (2) Other instruments and materials: dry facial tissue, 75% alcohol, lens cleaning paper, positioning card, hair band, hairpin, etc.

[0171] 3.5 Test samples and grouping;

[0172] Samples and groups refer to Table 8;

[0173] Table 8 Grouping information

[0174]

[0175] 3.6 Test results:

[0176] 3.6.1 Test results of group A: The efficacy test results of the control group and Example 1 refer to Table 9 (improvement rate / %);

[0177] Table 9 Test results of group A

[0178]

[0179] 3.6.1 Test results of group B: For the efficacy test results of the control group and Example 5, refer to Table 10 (improvement rate / %);

[0180] Table 10 Test results of group B

[0181]

[0182] Note: ns indicates no statistically significant difference, P value ≥ 0.05; * indicates significant difference, P value < 0.05; ** indicates very significant difference, P value < 0.01.

[0183] 3.6 Test results:

[0184] The test results showed that, compared with the control group, Examples 1 and 5 had the effects of repairing, enhancing skin elasticity, tightening, and improving cheek wrinkles.

[0185] The embodiments presented herein are only embodiments selected according to the combination of all possible embodiments. The appended claims should not be limited by the embodiments describing the present invention. Some numerical ranges used in the claims include sub-ranges therein, and the changes in these ranges should also be covered by the appended claims.

Claims

1. A soothing, firming and anti-wrinkle composition, characterized in that: Composed of Annona mume fruit extract and Withania somnifera root extract; The weight ratio of the cherimoya fruit extract to the withania somnifera root extract is 0.05-5:0.05-3.5; The content of the active ingredient of the Annona chebula fruit extract is 1wt%; The content of effective ingredients in the Withania somnifera root extract is 5.56 wt %.

2. Use of the soothing, firming and anti-wrinkle composition according to claim 1 in preparing cosmetics.

3. A cosmetic, characterized in that: Contains the soothing, firming and anti-wrinkle composition as claimed in claim 1.

4. The cosmetic according to claim 3, characterized in that: The invention contains 0.015 to 8.5 wt % of a soothing, firming and anti-wrinkle composition.

5. The cosmetic according to claim 4, characterized in that: The invention contains 0.1 to 8.5 wt % of a soothing, firming and anti-wrinkle composition.

Images